Powell’s speech, Nvidia’s chips, Meta deal - what’s moving markets
Andrew Dudum, the CEO of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of stock transactions, primarily selling shares of the company’s Class A Common Stock. According to a filing with the Securities and Exchange Commission, Dudum sold shares worth approximately $10.23 million on February 18, 2025. The sale prices ranged from $57.8526 to $59.6889 per share.
In addition to these sales, Dudum exercised stock options to acquire shares at an exercise price of $2.43 per share, totaling $304,564. Following these transactions, Dudum’s direct ownership stood at 108,015 shares, with additional shares held indirectly through various trusts. The company maintains strong financial health, with InvestingPro assigning it a "GREAT" overall score, supported by liquid assets exceeding short-term obligations and moderate debt levels.
These transactions were conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell company stock in accordance with insider trading laws. For deeper insights into HIMS’s valuation, financial health, and growth prospects, investors can access the comprehensive Pro Research Report available exclusively on InvestingPro, along with 18 additional key ProTips for informed decision-making.
In other recent news, Hims & Hers Health, Inc. reported significant developments that have caught the attention of investors. The company experienced a remarkable 104% year-over-year increase in online sales for January, with GLP-1 drugs now accounting for about 40% of its gross online sales. Analysts from BofA Securities have adjusted their first-quarter 2025 online revenue projections for Hims & Hers to range between $551 million and $574 million, exceeding the Visible Alpha consensus estimate of $489.4 million. Despite this optimistic forecast, BofA maintains an Underperform rating on the stock, with a revised price target of $21.
Additionally, Hims & Hers recently acquired Trybe Labs, an at-home lab testing facility, to enhance its personalized healthcare offerings. This acquisition aims to integrate at-home testing services, including blood draws, to provide more comprehensive data for clinical decision-making. Analysts from Canaccord Genuity and BTIG have responded positively to these developments, with Canaccord raising the company’s price target to $68 and maintaining a Buy rating, while BTIG increased its target to $85, also maintaining a Buy rating. Both firms express confidence in Hims & Hers’ growth prospects, highlighting its ability to expand healthcare services and capitalize on market trends. The acquisition and subsequent analyst upgrades reflect growing investor confidence in the company’s strategic direction and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.